Pediatric Clinical Trials Market

Market Insights on Pediatric Clinical Trials Market covering sales outlook, demand forecast & up-to-date key trends

Pediatric Clinical Trials Market by Phase Type, Study Design, Therapeutic Areas & Region - Forecast 2022 – 2032

Pediatric Clinical Trials Market Snapshot (2022-2032)

[307 Pages Report] According to Future Market Insights, the global pediatric clinical trials Market is projected to grow steadily at a 5.3% value CAGR, during the forecast period 2022-2032. Earlier in 2021, this market was projected to have a global market valuation worth US$ 15 Billion and is expected to reach a sum of US$ 26.47 Billion by 2032.

Global Growth Rate (2022-2032)	5.3% CAGR
Estimated Market Value in 2021	US$ 15 Billion
Projected Market Value in 2022	US$ 15.8 Billion
Projected Market Value by 2032	US$ 26.47 Billion

Due to unmet healthcare needs in the pediatric patient population, there is a considerable product pipeline in the clinical phase of development. In the foreseeable future, the market will benefit from a robust medication development pipeline. Furthermore, in 2021, there were over 1,300 industry-sponsored pediatric clinical studies underway spanning a wide range of therapeutic categories, including communicable diseases, genetic disorders, neurologic issues, and numerous types of cancer.

Increasing pediatric medicine awareness, outsourcing in-house clinical trials to CROs, and the Increasing Burden of Pediatric Diseases such as Diabetes are projected to drive market growth globally. By region, North America is observed to have a substantial proportion of the pediatric clinical trial market, and this trend is projected to continue during the projection period.

The United States has the region's most lucrative market. The rising prevalence of disorders in the country's pediatric population is strengthening research initiatives to produce particular medications and expanding the number of clinical trials. This, together with other factors, is driving demand for the worldwide pediatric clinical trials market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Prominent Growth Drivers Influencing Pediatric Clinical Trials Industry

Increased Incidence of Chronic Diseases to accelerate Market Growth

The growing demand for innovative vaccines and biological products to treat infectious illnesses such as measles, polio, mumps, TB, rubella, influenza, whooping cough, chickenpox, malaria, and staphylococcus pharyngitis is likely to fuel market expansion. According to the World Health Organization (WHO) 2021, over 85 percent of infants worldwide are vaccinated against 27 illnesses; yet, 19.4 million children are unvaccinated, resulting in the deaths of 2-3 million children per year. According to the Centers for Disease Control and Prevention (CDC) fact page, in 2021, over 471,000 children in the United States had active epilepsy, accounting for approximately 0.6 percent of children aged 0-17 years.

At the same time, diabetes is a major concern among children nowadays. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, around 464 million children globally had diabetes in 2021. One million of these people (children and adolescents under the age of 20) have type 1 diabetes.

Rising parental awareness of pediatric clinical trials for dangerous infections and chronic disorders, as well as a substantial number of CROs performing pediatric studies, are driving the market. Autism is one of the most frequent childhood disorders. According to the CDC, one in every 44 children in the United States will have autism by 2021. The increased prevalence of autism among children is expected to propel the market for autism clinical trials, promoting pediatric clinical market growth globally.

Shifting In-house Clinical Trials to CROs to augment the market growth

The pharmaceutical business has increasingly shifted from in-house clinical research to contract research organizations during the previous decade (CRO). According to the Tufts University in association with ICON PLC on CRO strategic alliances, it is anticipated that by 2022, 72% of all clinical trials would have been moved to CROs worldwide. CROs' roles are becoming more crucial as they get more active in clinical research and are viewed as more considered partners, offering access not only to devoted experts but also to patients all over the world.

Both the Food and drug administration and the European Medicines Agency (EMA) have made significant revisions to their standards, and most clinical studies now require a pediatric component. The expansion of these pediatric studies has also resulted in the establishment of pediatric CROs, such as Paidion Research, the first global CRO dedicated solely to pediatric health research. Many CROs are merging in order to raise their profiles and improve their services. Synteract, for example, bought Pediatric CRO KinderPharm to bolster its pediatric development center, which provides pharmacometric modeling and clinical trial simulation technology, as well as juvenile formulation and toxicological services. Such advancements in CROs have fueled the practice of outsourcing in-house clinical trials to CROs.

Pediatric Clinical Trials Market Download Report Brochure

What could possibly hinder Pediatric Clinical Trials Deployment?

Strict Regulations during the Pandemic and Risk among Children will restrict the Market’s Growth

Pediatric clinical studies were suspended during the pandemic to limit virus spread. This had an impact on the recruitment of young patients for new clinical studies. Such occurrences are likely to have a detrimental impact on market growth.

The high termination rate of pediatric clinical trials for a variety of reasons is projected to stifle expansion in the pediatric clinical trials market. Pediatric studies have a high failure rate due to factors such as patient accrual. Other concerns include behavioral issues and trial conduct issues such as improper dosing, formulation difficulty, and informative termination, as well as regulatory issues and medication toxicity during clinical studies. According to the US Food and Drug Administration, around 30 to 45% of pediatric trials fail to show safety, efficacy, or result in a labeled indication for pediatric use, resulting in their cancellation.

Differences in the acceptable degree of risk to which children may be exposed in clinical studies are also a problem. The requirement to preserve equipoise within study arms by balancing risks across groups complicates study design, enrollment, and patient consent. When this is done, the choice to enroll a child in a clinical study can be made on the same risk/benefit basis as the non research alternative for care. In reality, regulatory rules in the United States limit the permitted risk exposure for children when there is no recognized direct benefit to them from participating in the study. Furthermore, when direct benefits are possible for a certain study, constraints are placed on the basis for risk exposure. These are going to be some of the serious concerns for the key players in the market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Pediatric Clinical Trials Market

Pediatric Clinical Trials Market:

Attributes	Pediatric Clinical Trials Market
CAGR (2022-2032)	5.3%
Market Value (2032)	US$ 18.44 Billion
Growth Factor	Increasing R&D investments by the pharmaceutical industry as a result of the high burden of chronic conditions among pediatrics, as well as the COVID-19 pandemic, have contributed significantly to the demand for the pediatric clinical trials market.
Opportunity	Decentralized trials have been gradually adopted to ease pediatric trials. Such collaborations are projected to accelerate pediatric clinical trials and enhance the adoption of decentralized trials.
Key Trends	The Australian Government's Medical Research Future Fund (MRFF) awarded the researchers USD 1.8 million in May 2022 to discover a therapy for juvenile idiopathic arthritis. Such measures help to grow the pediatric clinical trial market.

Omics Based Clinical Trials Market:

Attributes	Omics Based Clinical Trials Market
CAGR (2022-2032)	8.1%
Market Value (2032)	US$ 61.71 Billion
Growth Factor	The Covid-19 pandemic, rising investment in the pharmaceutical sector by prominent participants to increase productivity, and the increasing frequency of chronic illnesses are the primary drivers of the increasing demands for omics-based clinical trials.
Opportunity	The single-cell multi-OMIC analysis is a breakthrough method that is advancing cancer medication research and therapeutic options. A growing number of biologics, the need for innovative technologies, and the demand for personalized treatments and orphan drugs are paving new avenues for this market.
Key Trends	In December, 2021, Rebus Biosystems Inc., a life science technology enterprise based in the United States, had acquired the assay assets and intellectual property of EEL Transcriptomics AB, a privately held company specialized on high-plex spatial transcriptomics with single-cell resolution.

Clinical Trial Logistics Market:

Attributes	Clinical Trial Logistics Market
CAGR (2022-2032)	7.2%
Market Value (2032)	US$ 6.45 Billion
Growth Factor	The increasing number of clinical trials done internationally, as well as technological advances in the supply chain, are likely to boost the global Clinical Trial Logistics Market.
Opportunity	This industry employs innovative IT systems that are adaptable enough to accommodate a wide range of changes. To fulfill rising demand, new umbrella, basket, and platform trials are being conducted, supplies are being pooled, and more sophisticated logistical and shelf-life challenges are being considered.
Key Trends	Technological advancements are having a favorable impact on the global market, both inbound and outward. As more Point of Care (POC) diagnostic technologies are created, there will be a tendency toward performing more local analysis and sending fewer blood, tissue, urine, and other samples to a central site for assessment.

Category-wise Insights

Which Phase insight is forecast to gain the Maximum Market Share?

Phase-II Clinical Trials likely to gain maximum share

Phase II trials category dominates the market, accounting for more than 33% of global revenue. Phase II clinical studies are designed to determine the pharmacological efficacy of new medicines. They are usually single-arm experiments, although they can also be multi-arm trials. Multiple-arm trials with or without control arms might be randomized or nonrandomized.

Children are subjected to phase II trials to examine the intervention's safety and efficacy. Phase II research includes a large number of pediatric individuals; also, studies in this stage are more sophisticated than those in previous phases. Generally, testing of pharmaceutical products in children is postponed until the trials reach phase III, which investigates efficacy, acceptability, and safety.

Although the deferral is intended to protect children from harm, it also indicates that children's access to potentially beneficial treatments will be delayed. Phase II trials have been shown to have higher success rates and are increasingly being conducted in the market due to their superior efficacy.

By Study Design, which Category is likely to benefit the most?

The Treatment Studies Segment is forecast to grow in the future

Treatment studies account for more than 66% of the global market's revenue. According to Clinicaltrials.gov, 63,060 pediatric trials were filed between 2001 and 2021, with 37,136 (68.1 percent) containing therapy studies. There were fewer drug studies conducted throughout time, although the majority of therapy pediatric trials were single site (61.4 percent), small-scale (58.9 percent), randomized (66.0 percent), and had no masking (56.9 percent).

Institutions (78.8 percent), industry (19.1 percent), NIH (National Institute of Health) (1.6 percent), and U.S. public agencies fund the majority of pediatric trial treatment studies (0.5 percent). This is one of the primary causes for the segment's rapid growth in the global market.

Which Therapeutic Area will gain prominence during the Forecast Period?

Oncology is expected to be the fastest growing during the forecast period

By therapeutics, oncology is expected to hold a high revenue share of more than 17% of the global market. Cancer is a leading cause of death worldwide. Cancer cases among youngsters under the age of 19 years are expected to reach 291,000 by 2040.

As per the American Cancer Society, an estimated 10,500 children under the age of 15 in the United States will be diagnosed with cancer in 2022. It also claims that pediatric cancer rates have risen in recent decades. Furthermore, According to clinicaltrials.gov, there were roughly 3,287 ongoing pediatric clinical trials for cancer in July 2021. The increased number of these trials is projected to boost the market.

The National Cancer Institute established the Molecular Characterization Initiative for Pediatric Tumors in March 2022. The Initiative is provided by the NCI's Childhood Cancer Data Initiative, which was established to encourage data exchange and the collecting of new data among pediatric oncology experts. With the growing number of pediatric cancer cases globally, many hospitals and institutions are focusing on the development of therapeutic medications, resulting in an increase in the number of pediatric clinical trials worldwide.

Country-wise Analysis

What is the Outlook of the North American pediatric clinical trials Market?

Increasing chronic diseases among the children in this region will drive this market

North America led the global pediatric clinical trials market, accounting for 45% of global sales. This is owing to the presence of a large number of pharmaceutical companies and contract research organizations (CROs) performing pediatric studies in the region.

The United States is predicted to have a considerable market share and to exhibit a similar trend during the projection period. According to clinicaltrials.gov, there were more than 1,365 ongoing pediatric clinical trials in the United States as of March 2022, representing a significant fraction of the global number of pediatric research operations. The high number of trials, as well as the high cost per treatment and patient, have had a significant impact on the market in the United States.

The rising prevalence of disorders in the country's pediatric population is strengthening research initiatives to produce particular medications and increasing the number of clinical trials. According to the National Diabetes Statistics Report 2021, an estimated 185,000 American children and adolescents were seen to be suffering from Type 1 diabetes in 2020, and this figure is expected to rise in the future years. This will necessitate rapid demand in this industry to combat these diseases.

Aside from that, public groups are taking active steps to fund pediatric research. For example, the current NIH funding for pediatric research is USD 4 billion. Such measures will contribute to the expansion of the market in this region.

How is the growth of pediatric clinical trials emerging in the APAC region?

Huge population with varied genetic defects in the APAC region to boost the market

Asia Pacific is expected to grow at the fastest rate over the forecast period, with a 25% market share. Due to the simplicity of regulatory compliance, low study expenses, and rapidly growing pediatric patient population, the Asia Pacific region has become a hotspot for conducting clinical trials.

APAC has a genetically varied population of approximately 4 billion individuals, many of whom may be treatment-naive in nations such as India and China. As a result, recruiting pediatric patients who match qualifying criteria may be simpler than in Western countries. Furthermore, APAC countries frequently have a big number of desirable patients who show lifestyle-related health and genetic disorders that were previously more widespread in the Western world. In India, for example, children are still born with a variety of genetic abnormalities and chronic diseases.

Furthermore, due to the high frequency of pediatric disorders, supportive activities boosting pediatric research in the region are propelling the regional market. For example, UNESCO reported in March 2022 that China is focusing on creating improvements in neuroscience to treat children with autism in the country.

Region-wise Market Share for the Pediatric Clinical Trials Market

North America	45%
APAC	25%
Europe	15%
Latin America	9%
Middle East & Africa	6%

Competitive Landscape

Due to the sheer presence of a few important players in the market with very few additional participants, the industry studied is consolidated. Market participants' primary strategies included trial initialization, acquisitions, and collaborations, among others.

Pfizer began a Phase 2/3 research for PAXLOVID tablets, which are especially intended to treat COVID-19 in young patients, in March 2022. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom start) and 88 percent (within five days of appearance of symptoms).
Novartis announced intentions to begin SMART, a Phase 3b clinical research to assess the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy, in April 2021. SMART is a multicenter, Phase 3b, single-arm, open-label study designed to assess the safety, tolerability, and efficacy of a one-time IV infusion of Zolgensma in pediatric patients with symptomatic SMA who have bi-allelic genetic changes in the SMN1 gene and any copy number of the SMN2 gene and weigh between 8.5 kg and 21 kg. The study will enroll 24 patients and will monitor them for a 12-month period.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.3% from 2022 to 2032
Market Value for 2022	US$ 15.8 Billion
Market Value for 2032	US$ 26.47 Billion
Base Year for Estimation	2021
Historical Data	2017-2021
Forecast Period	2022-2032
Quantitative Units	USD Billion for Value
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Phase Study Design Therapeutic Areas Region
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Key Countries Profiled	U.S Canada Germany U.K France Italy Spain Nordics Japan China South Korea India ASEAN Brazil Mexico South Africa Saudi Arabia UAE
Key Companies Profiled	Synteract ICON Plc. Syneos Health Medpace, Inc PPD Inc. Premier Research LabCorp Drug Development QPS Holding Pfizer Inc. The Emmes Company, LLC IQVIA Inc.
Report Customization & Pricing	Available upon Request

Key Segments Covered in the Pediatric Clinical Trials Market Report

Pediatric Clinical Trials Market by Phase Type:

Phase I Pediatric Clinical Trials
Phase II Pediatric Clinical Trials
Phase III Pediatric Clinical Trials
Phase IV Pediatric Clinical Trials

Pediatric Clinical Trials Market by Study Design:

Treatment Studies of Pediatric Clinical Trials
Observational Studies of Pediatric Clinical Trials

Pediatric Clinical Trials Market by Therapeutic Areas:

Pediatric Clinical Trials for Infectious Diseases
Pediatric Clinical Trials for Oncology
Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
Pediatric Clinical Trials for Respiratory Disorders
Pediatric Clinical Trials for Mental Health Disorders
Pediatric Clinical Trials for Other Therapeutic Areas

Pediatric Clinical Trials Market by Region:

North American Pediatric Clinical Trials Market
Europe Pediatric Clinical Trials Market
Asia Pacific Pediatric Clinical Trials Market
Middle East & African Pediatric Clinical Trials Market
Latin America Pediatric Clinical Trials Market

Frequently Asked Questions

At what rate did the pediatric clinical trials Market flourish from 2017-2021?

From 2017-2021, the pediatric clinical trials Market grew at a CAGR of 5%.

What is the future outlook of the global pediatric clinical trials Market during the forecast period?

The global pediatric clinical trials Market is expected to grow with a 5.3% CAGR and is projected to gain a market size of US$ 26.47 Billion by 2032

Which segment is going to dominate the global pediatric clinical trials Market during 2022-2032?

In 2021, the treatment studies segment dominated the global market with 66% market share

What will be the outlook of the offline pediatric clinical trial distribution channel segment during the forecast period?

The phase II trials segment is expected to occupy a global market share of 33%

How did the pediatric clinical trials market in North America flourish during 2021?

The North American pediatric clinical trials market will hold a 45% global market share

What was the outlook of the APAC pediatric clinical trials market during 2021?

APAC is expected to acquire a global market share of 25% in 2021.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Investment Feasibility Matrix

3.6. PESTLE and Porter’s Analysis

3.7. Regulatory Landscape

3.7.1. By Key Regions

3.7.2. By Key Countries

3.8. Regional Parent Market Outlook

4. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Phase

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Mn) Analysis By Phase, 2017-2021

5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Phase, 2022-2032

5.3.1. Phase I

5.3.2. Phase II

5.3.3. Phase III

5.3.4. Phase IV

5.4. Y-o-Y Growth Trend Analysis By Phase, 2017-2021

5.5. Absolute $ Opportunity Analysis By Phase, 2022-2032

6. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Study Design

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Mn) Analysis By Study Design, 2017-2021

6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Study Design, 2022-2032

6.3.1. Treatment Studies

6.3.2. Observational Studies

6.4. Y-o-Y Growth Trend Analysis By Study Design, 2017-2021

6.5. Absolute $ Opportunity Analysis By Study Design, 2022-2032

7. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Areas

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Mn) Analysis By Therapeutic Areas, 2017-2021

7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapeutic Areas, 2022-2032

7.3.1. Infectious Diseases

7.3.2. Oncology

7.3.3. Autoimmune / Inflammatory Diseases

7.3.4. Respiratory Disorders

7.3.5. Mental Health Disorders

7.3.6. Others

7.4. Y-o-Y Growth Trend Analysis By Therapeutic Areas, 2017-2021

7.5. Absolute $ Opportunity Analysis By Therapeutic Areas, 2022-2032

8. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Region

8.1. Introduction

8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

8.3.1. North America

8.3.2. Latin America

8.3.3. Europe

8.3.4. Asia Pacific

8.3.5. Middle East and Africa

8.4. Market Attractiveness Analysis By Region

9. North America Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country

9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

9.2.1. By Country

9.2.1.1. U.S.

9.2.1.2. Canada

9.2.2. By Phase

9.2.3. By Study Design

9.2.4. By Therapeutic Areas

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Phase

9.3.3. By Study Design

9.3.4. By Therapeutic Areas

9.4. Key Takeaways

10. Latin America Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country

10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

10.2.1. By Country

10.2.1.1. Brazil

10.2.1.2. Mexico

10.2.1.3. Rest of Latin America

10.2.2. By Phase

10.2.3. By Study Design

10.2.4. By Therapeutic Areas

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Phase

10.3.3. By Study Design

10.3.4. By Therapeutic Areas

10.4. Key Takeaways

11. Europe Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country

11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

11.2.1. By Country

11.2.1.1. Germany

11.2.1.2. Italy

11.2.1.3. France

11.2.1.4. U.K.

11.2.1.5. Russia

11.2.1.6. BENELUX

11.2.1.7. Rest of Europe

11.2.2. By Phase

11.2.3. By Study Design

11.2.4. By Therapeutic Areas

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Phase

11.3.3. By Study Design

11.3.4. By Therapeutic Areas

11.4. Key Takeaways

12. Asia Pacific Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country

12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.1.4. Rest of Asia Pacific

12.2.2. By Phase

12.2.3. By Study Design

12.2.4. By Therapeutic Areas

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Phase

12.3.3. By Study Design

12.3.4. By Therapeutic Areas

12.4. Key Takeaways

13. Middle East and Africa Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country

13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

13.2.1. By Country

13.2.1.1. GCC Countries

13.2.1.2. South Africa

13.2.1.3. Turkey

13.2.1.4. Rest of Middle East and Africa

13.2.2. By Phase

13.2.3. By Study Design

13.2.4. By Therapeutic Areas

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Phase

13.3.3. By Study Design

13.3.4. By Therapeutic Areas

13.4. Key Takeaways

14. Key Countries Pediatric Clinical Trials Market Analysis

14.1. U.S.

14.1.1. Pricing Analysis

14.1.2. Market Share Analysis, 2021

14.1.2.1. By Phase

14.1.2.2. By Study Design

14.1.2.3. By Therapeutic Areas

14.2. Canada

14.2.1. Pricing Analysis

14.2.2. Market Share Analysis, 2021

14.2.2.1. By Phase

14.2.2.2. By Study Design

14.2.2.3. By Therapeutic Areas

14.3. Brazil

14.3.1. Pricing Analysis

14.3.2. Market Share Analysis, 2021

14.3.2.1. By Phase

14.3.2.2. By Study Design

14.3.2.3. By Therapeutic Areas

14.4. Mexico

14.4.1. Pricing Analysis

14.4.2. Market Share Analysis, 2021

14.4.2.1. By Phase

14.4.2.2. By Study Design

14.4.2.3. By Therapeutic Areas

14.5. Germany

14.5.1. Pricing Analysis

14.5.2. Market Share Analysis, 2021

14.5.2.1. By Phase

14.5.2.2. By Study Design

14.5.2.3. By Therapeutic Areas

14.6. Italy

14.6.1. Pricing Analysis

14.6.2. Market Share Analysis, 2021

14.6.2.1. By Phase

14.6.2.2. By Study Design

14.6.2.3. By Therapeutic Areas

14.7. France

14.7.1. Pricing Analysis

14.7.2. Market Share Analysis, 2021

14.7.2.1. By Phase

14.7.2.2. By Study Design

14.7.2.3. By Therapeutic Areas

14.8. U.K.

14.8.1. Pricing Analysis

14.8.2. Market Share Analysis, 2021

14.8.2.1. By Phase

14.8.2.2. By Study Design

14.8.2.3. By Therapeutic Areas

14.9. Russia

14.9.1. Pricing Analysis

14.9.2. Market Share Analysis, 2021

14.9.2.1. By Phase

14.9.2.2. By Study Design

14.9.2.3. By Therapeutic Areas

14.10. BENELUX

14.10.1. Pricing Analysis

14.10.2. Market Share Analysis, 2021

14.10.2.1. By Phase

14.10.2.2. By Study Design

14.10.2.3. By Therapeutic Areas

14.11. China

14.11.1. Pricing Analysis

14.11.2. Market Share Analysis, 2021

14.11.2.1. By Phase

14.11.2.2. By Study Design

14.11.2.3. By Therapeutic Areas

14.12. Japan

14.12.1. Pricing Analysis

14.12.2. Market Share Analysis, 2021

14.12.2.1. By Phase

14.12.2.2. By Study Design

14.12.2.3. By Therapeutic Areas

14.13. South Korea

14.13.1. Pricing Analysis

14.13.2. Market Share Analysis, 2021

14.13.2.1. By Phase

14.13.2.2. By Study Design

14.13.2.3. By Therapeutic Areas

14.14. GCC Countries

14.14.1. Pricing Analysis

14.14.2. Market Share Analysis, 2021

14.14.2.1. By Phase

14.14.2.2. By Study Design

14.14.2.3. By Therapeutic Areas

14.15. South Africa

14.15.1. Pricing Analysis

14.15.2. Market Share Analysis, 2021

14.15.2.1. By Phase

14.15.2.2. By Study Design

14.15.2.3. By Therapeutic Areas

14.16. Turkey

14.16.1. Pricing Analysis

14.16.2. Market Share Analysis, 2021

14.16.2.1. By Phase

14.16.2.2. By Study Design

14.16.2.3. By Therapeutic Areas

15. Market Structure Analysis

15.1. Competition Dashboard

15.2. Competition Benchmarking

15.3. Market Share Analysis of Top Players

15.3.1. By Regional

15.3.2. By Phase

15.3.3. By Study Design

15.3.4. By Therapeutic Areas

16. Competition Analysis

16.1. Competition Deep Dive

16.1.1. ICON plc

16.1.1.1. Overview

16.1.1.2. Product Portfolio

16.1.1.3. Profitability by Market Segments

16.1.1.4. Sales Footprint

16.1.1.5. Strategy Overview

16.1.1.5.1. Marketing Strategy

16.1.2. Syneos Health

16.1.2.1. Overview

16.1.2.2. Product Portfolio

16.1.2.3. Profitability by Market Segments

16.1.2.4. Sales Footprint

16.1.2.5. Strategy Overview

16.1.2.5.1. Marketing Strategy

16.1.3. Medpace, Inc.

16.1.3.1. Overview

16.1.3.2. Product Portfolio

16.1.3.3. Profitability by Market Segments

16.1.3.4. Sales Footprint

16.1.3.5. Strategy Overview

16.1.3.5.1. Marketing Strategy

16.1.4. PPD Inc.

16.1.4.1. Overview

16.1.4.2. Product Portfolio

16.1.4.3. Profitability by Market Segments

16.1.4.4. Sales Footprint

16.1.4.5. Strategy Overview

16.1.4.5.1. Marketing Strategy

16.1.5. Premier Research

16.1.5.1. Overview

16.1.5.2. Product Portfolio

16.1.5.3. Profitability by Market Segments

16.1.5.4. Sales Footprint

16.1.5.5. Strategy Overview

16.1.5.5.1. Marketing Strategy

16.1.6. LabCorp Drug Development

16.1.6.1. Overview

16.1.6.2. Product Portfolio

16.1.6.3. Profitability by Market Segments

16.1.6.4. Sales Footprint

16.1.6.5. Strategy Overview

16.1.6.5.1. Marketing Strategy

16.1.7. QPS Holdings

16.1.7.1. Overview

16.1.7.2. Product Portfolio

16.1.7.3. Profitability by Market Segments

16.1.7.4. Sales Footprint

16.1.7.5. Strategy Overview

16.1.7.5.1. Marketing Strategy

16.1.8. Pfizer Inc.

16.1.8.1. Overview

16.1.8.2. Product Portfolio

16.1.8.3. Profitability by Market Segments

16.1.8.4. Sales Footprint

16.1.8.5. Strategy Overview

16.1.8.5.1. Marketing Strategy

16.1.9. The Emmes Company, LLC

16.1.9.1. Overview

16.1.9.2. Product Portfolio

16.1.9.3. Profitability by Market Segments

16.1.9.4. Sales Footprint

16.1.9.5. Strategy Overview

16.1.9.5.1. Marketing Strategy

16.1.10. IQVIA Inc.

16.1.10.1. Overview

16.1.10.2. Product Portfolio

16.1.10.3. Profitability by Market Segments

16.1.10.4. Sales Footprint

16.1.10.5. Strategy Overview

16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

List of Tables

Table 1: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032

Table 3: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032

Table 4: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032

Table 5: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032

Table 7: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032

Table 8: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032

Table 9: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032

Table 11: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032

Table 12: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032

Table 13: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032

Table 15: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032

Table 16: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032

Table 17: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 18: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032

Table 19: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032

Table 20: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032

Table 21: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032

Table 23: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032

Table 24: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032

Figure 2: Global Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032

Figure 3: Global Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032

Figure 4: Global Pediatric Clinical Trials Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 6: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032

Figure 9: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032

Figure 10: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032

Figure 11: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032

Figure 12: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032

Figure 13: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032

Figure 14: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032

Figure 15: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032

Figure 16: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032

Figure 17: Global Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032

Figure 18: Global Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032

Figure 19: Global Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032

Figure 20: Global Pediatric Clinical Trials Market Attractiveness by Region, 2022-2032

Figure 21: North America Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032

Figure 22: North America Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032

Figure 23: North America Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032

Figure 24: North America Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 26: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032

Figure 29: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032

Figure 30: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032

Figure 31: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032

Figure 32: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032

Figure 33: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032

Figure 34: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032

Figure 35: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032

Figure 36: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032

Figure 37: North America Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032

Figure 38: North America Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032

Figure 39: North America Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032

Figure 40: North America Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032

Figure 42: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032

Figure 43: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032

Figure 44: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 46: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032

Figure 49: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032

Figure 50: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032

Figure 51: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032

Figure 52: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032

Figure 53: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032

Figure 54: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032

Figure 55: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032

Figure 56: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032

Figure 57: Latin America Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032

Figure 58: Latin America Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032

Figure 59: Latin America Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032

Figure 60: Latin America Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032

Figure 61: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032

Figure 62: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032

Figure 63: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032

Figure 64: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 66: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032

Figure 69: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032

Figure 70: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032

Figure 71: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032

Figure 72: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032

Figure 73: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032

Figure 74: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032

Figure 75: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032

Figure 76: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032

Figure 77: Europe Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032

Figure 78: Europe Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032

Figure 79: Europe Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032

Figure 80: Europe Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032

Figure 82: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032

Figure 83: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032

Figure 84: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 86: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032

Figure 89: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032

Figure 90: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032

Figure 91: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032

Figure 92: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032

Figure 93: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032

Figure 94: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032

Figure 95: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032

Figure 96: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032

Figure 97: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032

Figure 98: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032

Figure 99: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032

Figure 100: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032

Figure 101: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032

Figure 102: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032

Figure 103: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032

Figure 104: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032

Figure 105: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 106: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032

Figure 109: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032

Figure 110: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032

Figure 111: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032

Figure 112: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032

Figure 113: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032

Figure 114: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032

Figure 115: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032

Figure 116: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032

Figure 117: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032

Figure 118: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032

Figure 119: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032

Figure 120: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032